2018 revenue at
- Half-year revenue down vs prior year, affected by the COVID-19 crisis
- -9.2% at current exchange rates at €363.7 million
- -8.4% at constant exchange rates (CER) at €367.1 million
- Gradual return to a normal level of activity in June
Villepinte,
In millions of euros, at | Change (%) | H1 2020 at current exchange rates | Change (%) | H1 2020 at constant exchange rates | Reported H1 2019 |
Sales in | -21.1% | 138.9 | -21.2% | 138.8 | 176.1 |
Sales in Other Markets | +0.1% | 224.8 | +1.7% | 228.3 | 224.5 |
Total | -9.2% | 363.7 | -8.4% | 367.1 | 400.6 |
Impact of the health crisis in
As expected, sales declined in most European countries. Revenue was down 21.1% at €138.9 million (€138.8 million at CER).
Revenue in the
In
Analysis of sales by activity
Diagnostic Imaging revenue was €308.4 million, compared with €354.6 million in the first half of 2019, down 13.0% (-11.9% at CER).
- MRI sales decreased 18.7% (same at CER), bringing reported revenue to €110.9 million, compared with €136.4 million in the same period last year. This decline was due to an unfavorable price effect related to the arrival of the generic of Dotarem® in most countries of the
-
Interventional Imaging continued to be driven by Lipiodol® sales. Its revenue totaled €36 million, up 3.1% (+1.9% at CER) from €34.9 million in the same period last year.
Reaffirmed confidence in the Group’s outlook
After April and May, with revenues down by around -30% compared with 2019, the Group saw encouraging signs of recovery in June with a gradual return to normal activity across all geographical regions. Despite the continued spread of the COVID-19 pandemic and the resulting reduction of short-term visibility,
[1] CER: At constant exchange rates. Amounts and rates of growth are calculated by canceling out the exchange rate effect, which is defined as the difference between the indicator’s value for period N, converted at the exchange rate for period N-1, and the indicator’s value for period N-1.
2 As a reminder, the
Upcoming events:
Presentation of half-year consolidated financial statements at
About
Forward-looking statements
Certain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.
These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the
For more information about
Contacts
Actifin |
Jérôme Estampes Chief Financial Officer +33 (0)1 45 91 50 00 | +33 (0)1 56 88 11 25 blehari@actifin.fr Press Jennifer Jullia +33 (0)1 56 88 11 19 jjullia@actifin.fr |
Attachment
- 07232020- Revenue at
June 30, 2020
Source:
2020 GlobeNewswire, Inc., source